絞り込み

16610

広告

運動は中高年から始めても遅くない (日経BP)

運動は総死亡、心血管疾患、癌のリスク低下に関係することが示されている。しかし、多くの研究では、ベースラインの運動量とアウトカムの関係を調べており、その後の生活習...

  1. 医学部受験「バブル」はひとまず終息しまし...
  2. 無給医、労基署による全大学病院の緊急点検...
  3. 転移性前立腺癌の治療はより早期に新規AR...
  4. しばしば誤嚥性肺炎の原因となる意外なあの...

ニュース一覧

Safety analysis of apixaban versus warfarin in patients with advanced kidney disease.

著者 Bowie M , Valencia V , Perez-Alvarez I , Tran MH
J Thromb Thrombolysis.2018 May 30 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (86view , 0users)

Full Text Sources

Medical

Miscellaneous

Anticoagulation in patients with advanced kidney disease, defined as those with an eGFR < 25 mL/min, including patients with end-stage renal disease on hemodialysis, remains an area of controversy and debate. Due to safety concerns regarding the increased risk for bleeding in this population, these patients have been excluded from all large-scale, randomized controlled trials to date. Warfarin and apixaban are both FDA-approved for use in this population and although warfarin remains the anticoagulant of choice, apixaban use is steadily increasing. This review combines relevant literature to better understand the risk versus benefit of anticoagulation in patients with severe kidney disease as well as the safety of apixaban versus warfarin in this population. High rates of bleed were found among both anticoagulants in those with severe kidney disease, suggesting that the risk for bleed associated with anticoagulation may not outweigh the benefit of treatment. Apixaban was found to be superior in rates of major bleed in those with ESRD on HD and may be superior to warfarin in those with an eGFR < 25 mL/min. However, large-scale, randomized clinical trials are needed to validate these results. With the continued development of novel agents there may be superior alternatives to apixaban and warfarin in those with severe kidney disease in the future.
PMID: 29846888 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード